沙特阿拉伯王国政府所属的官方政府网站。
周四 25 6月 2026
沙特官方政府网站的域名以下列后缀结尾 gov.sa
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
政府网站使用以下协议。 HTTPS 用于加密和安全。
沙特阿拉伯王国所有政府机构的官方网站均以 .gov.sa 结尾。
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| Jectin-12® (Cyanocobalamin) | Cyanocobalamin and the risk of medication error. |
||
| Xeljanz® (Tofacitinib) | Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis. |
||
| Genvoya ® (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) | Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy. |
||
| Dapagliflozin | Risk of Fournier’s gangrene (necrotising fasciitis of the perineum) with Sodium-glucose-Co-Transporter 2 inhibitors (SGLT2i). |
||
| Adenuric® (Febuxostat) | Febuxostat (adenuric®): Higher rate of cardiovascular death in gout patients with established cardiovascular disease. |
||
| Belimumab | Benlysta (Belimumab) and Risk of serious Depression and/ or Suicidal ideation or Behavior or self-injury. |
||
| Atezolizumab | TECENTRIQ® (atezolizumab): A New Important Identified Risk: Immune-related Myositis. |
||
| Canagliflozin | Risk of Fournier´s gangrene (necrotising fasciitis of the perineum) with Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i). |
||
| Pembrolizumab | Keytruda (pembrolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy. |
||
| Empagliflozin | Direct Healthcare Professional Communication on the association of Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i) with Risk of Fournier´s gangrene (necrotising fasciitis of the perineum). |
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。